SCHEMBL4134836

SCHEMBL4134836

C=Cn1cnc2c(NCCN(C)C)ncnc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.48
TMIGD3 P0DMS9 4/20 0.43
ADORA2A P29274 4/20 0.43
ADORA1 P30542 4/20 0.43
ADORA2B P29275 1/20 0.43
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 2/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
ALPG P10696 1/20 0.42
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CDK1 P06493 3/20 0.41
CCNB2 O95067 2/20 0.41
CCNB1 P14635 2/20 0.41
CCNB3 Q8WWL7 2/20 0.41
HTT P42858 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143566 0.92 SRC (0.46) SRCTMIGD3ADORA2AADORA1ADORA2B
Dimethylamine SCHEMBL4143569 0.83 SRC (0.49) SRCTMIGD3ADORA2AADORA1ADORA2B
Dimethylamine SCHEMBL4134839 0.80 SRC (0.51) SRCTMIGD3ADORA2AADORA1ADORA2B
SCHEMBL4120821 0.77 YTHDC1 (0.60) SRCADORA2AADORA1ADORA2BRAB9A
SCHEMBL18179484 0.70 ADORA2A (0.49) TMIGD3ADORA2AADORA1ADORA2BRAB9A
SCHEMBL4128648 0.70 ADORA1 (0.56) SRCADORA2AADORA1ADORA2B
SCHEMBL13811638 0.69 SRC (0.47) SRCADORA2AADORA1ADORA2BRAB9A
SCHEMBL4121599 0.69 SRC (0.67) SRCRAB9AKDM4ENPC1HPGD
SCHEMBL22326727 0.66 ADORA2A (0.69) TMIGD3ADORA2AADORA1ADORA2BRAB9A
SCHEMBL8497990 0.66 GAA (0.48) RAB9AKDM4EPOLBGAAALPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586566-B2 Unsaturated heterocyclic derivatives ARIAD PHARMACEUTICALS, INC. (US) 2013-11-19 US disclosed
US-20120178716-A1 Unsaturated Heterocyclic Derivatives ARIAD PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-8071609-B2 Unsaturated heterocyclic derivatives ARIAD PHARMACEUTICALS, INC. (US) 2011-12-06 US disclosed
US-20090156596-A1 Unsaturated Heterocyclic Derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156596-A1 Unsaturated Heterocyclic Derivatives CYP2F1, CYP2J2, ALOX5 SRC 4651/4885TMIGD3 2692/4885ADORA2A 2218/4885
US-20120178716-A1 Unsaturated Heterocyclic Derivatives CYP2F1, CYP2J2, ALOX5 SRC 4651/4885TMIGD3 2692/4885ADORA2A 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.